SteadyMed Ltd. (NASDAQ:STDY) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On May12, 2017, SteadyMed Ltd issued a press release announcing
its financial results for the quarter ended March31, 2017. A copy
of this press release is attached hereto as Exhibit99.1.
The information in this Current Report on Form8-K, including
Exhibit99.1, shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liability of that section, nor
shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act,
whether made before or after the date hereof, except as expressly
set forth by specific reference in such filing to this Current
Report on Form8-K.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
|
Exhibit Number |
|
ExhibitDescription |
|
99.1 |
Press Release, dated May12, 2017 |
About SteadyMed Ltd. (NASDAQ:STDY)
SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH). It is also developing approximately two products for the treatment of post-surgical and acute pain in the home setting, which include bupivacaine PatchPump for local anesthesia post-surgery and ketorolac PatchPump for short-term management of moderately severe acute pain. Its product candidates are enabled by its PatchPump. Its Trevyent offers a way of administration of treprostinil for subcutaneous or intravenous treatment of PAH patients. The Company’s ketorolac At Home Patient Analgesia (AHPA) product candidate is used for the short-term (approximately five days) management of moderately severe acute pain that requires analgesia at the opioid level in a post-surgical setting. SteadyMed Ltd. (NASDAQ:STDY) Recent Trading Information
SteadyMed Ltd. (NASDAQ:STDY) closed its last trading session down -0.05 at 7.00 with 48,118 shares trading hands.
